Business Context and Reporting Period
This Form 8-K is filed by PowerUp Acquisition Corp. (not Aspire Biopharma Holdings, Inc., which is the target of a potential business combination) for the reporting period of October 2, 2024. The filing discloses the entry into a material definitive agreement regarding a fee modification related to a prior loan arrangement.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, or liquidity metrics. The only specific financial figure disclosed is a contingent liability:
- Modified Promissory Note Fee: $1,000,000 payable to SRIRAMA Associates, LLC (Sponsor) upon the successful closing of a business combination with Aspire Biopharma, Inc.
Material Changes
The filing details a change in the compensation structure for the Sponsor regarding a $2,000,000 loan originally made to Visiox Pharmaceuticals, Inc. in December 2023:
- Termination of Prior Agreement: The original Business Combination Agreement (BCA) with Visiox was terminated on July 22, 2024, which voided the Sponsor's right to the original $2,000,000 fee.
- New Agreement: On October 2, 2024, the Company and Sponsor entered into a new Promissory Note Fee Agreement. This agreement recognizes the risk taken by the Sponsor and establishes a new fee of $1,000,000, contingent on the closing of a business combination with Aspire Biopharma, Inc.
Outlook, Risks, and Contingencies
Contingent Liability: The $1,000,000 fee is not an immediate cash outflow but is contingent upon the successful closing of a business combination with Aspire Biopharma, Inc. If the deal does not close, the fee is not payable under this agreement.
Management Commentary: The filing states that the Sponsor took a "significant risk" on behalf of the Company by entering into the original promissory note, justifying the compensation despite the termination of the original deal.
Risks: The filing does not explicitly list new risk factors, but the contingent nature of the fee implies that the Company's ability to close a future transaction is a critical variable for this liability.
Investor Verification Checklist
- Verify the current status of the proposed business combination between PowerUp Acquisition Corp. and Aspire Biopharma, Inc.
- Confirm the terms of the "Promissory Note Fee Agreement" filed as Exhibit 2.1 to understand any additional conditions for the $1,000,000 payment.
- Review the Company's cash position to assess the ability to fund the $1,000,000 fee if the transaction closes.
- Note that the registrant is PowerUp Acquisition Corp., not Aspire Biopharma Holdings, Inc., as indicated in the request metadata.